Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Intravitreal Aflibercept for Submacular Hemorrhage in AMD
NCT03169660Phase 4Completed
- Sponsor
- Kim's Eye Hospital
- Start
- Dec 2015
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Kim's Eye Hospital. Primary endpoint: Changes in Early Treatment of Diabetic Retinopathy Study visual acuity Score at 56 weeks. Started Dec 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03169660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169660.